Equities research analysts at Robert W. Baird started coverage on shares of Inflarx (NASDAQ:IFRX) in a report released on Monday, January 28th, MarketBeat.com reports. The firm set an “outperform” rating and a $62.00 price target on the stock. Robert W. Baird’s target price points to a potential upside of 87.99% from the company’s current price.
A number of other research analysts also recently weighed in on the stock. Credit Suisse Group assumed coverage on shares of Inflarx in a research report on Monday, December 10th. They set an “outperform” rating and a $47.00 price objective on the stock. ValuEngine upgraded shares of Inflarx from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st. Finally, Zacks Investment Research upgraded shares of Inflarx from a “sell” rating to a “hold” rating in a research report on Tuesday, November 13th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $50.00.
Shares of IFRX opened at $32.98 on Monday. Inflarx has a fifty-two week low of $20.31 and a fifty-two week high of $42.83. The stock has a market capitalization of $776.74 million, a price-to-earnings ratio of -11.22 and a beta of -0.94.
Inflarx (NASDAQ:IFRX) last posted its quarterly earnings results on Wednesday, November 21st. The company reported ($0.31) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.41) by $0.10. As a group, equities analysts expect that Inflarx will post -1.33 EPS for the current year.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Millennium Management LLC grew its stake in Inflarx by 18.1% during the fourth quarter. Millennium Management LLC now owns 72,153 shares of the company’s stock valued at $2,624,000 after acquiring an additional 11,080 shares in the last quarter. Paloma Partners Management Co purchased a new position in Inflarx during the fourth quarter valued at $526,000. RA Capital Management LLC grew its stake in Inflarx by 6.0% during the fourth quarter. RA Capital Management LLC now owns 2,085,089 shares of the company’s stock valued at $75,835,000 after acquiring an additional 117,241 shares in the last quarter. Bank of America Corp DE purchased a new position in Inflarx during the fourth quarter valued at $657,000. Finally, Polar Capital LLP grew its stake in Inflarx by 54.4% during the fourth quarter. Polar Capital LLP now owns 141,887 shares of the company’s stock valued at $5,160,000 after acquiring an additional 50,000 shares in the last quarter. 56.70% of the stock is owned by institutional investors.
Inflarx Company Profile
InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company’s lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.
Recommended Story: Initial Public Offering (IPO)
Receive News & Ratings for Inflarx Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Inflarx and related companies with MarketBeat.com’s FREE daily email newsletter.